ERBB2 and breast carcinoma: The significance of these findings lies in their being consistent with findings from previous research on adaptive drug resistance mechanisms in HER2-positive breast cancer, emphasising the importance of metabolic reprogramming and protein turnover in developing resistance to HER2-targeted therapies [55,56].